全球连续性肾脏替代治疗市场 – 行业趋势及 2030 年预测

 连续性肾脏替代治疗市场分析及规模

根据 2018 年《临床与诊断研究杂志》（JCDR）上发表的一项前瞻性观察研究，该研究针对 100 名重症患者，结果显示，在印度，AKI 的发生率为 17.3/1,000 人。为了利用新兴市场的巨大增长机会，参与者越来越关注战略发展，以增加他们在这些市场的份额并接触到大量客户。此外，由于数据要求不那么严格，亚太地区的监管政策更具适应性且更利于商业发展。再加上成熟市场（欧洲、日本和澳大利亚）竞争加剧，将鼓励 CRRT 产品制造商专注于新兴市场。

Data Bridge Market Research 分析，2022 年持续性肾脏替代治疗市场规模为 12.5992 亿美元，预计到 2030 年将达到 24.198 亿美元，2023 年至 2030 年预测期内的复合年增长率为 8.5%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

连续性肾脏替代治疗市场范围和细分  

Market Definition

Continuous renal replacement therapy (CRRT) is a common treatment for critically ill patients with acute kidney injury, especially hemodynamically unstable patients. Acute kidney injury (AKI) is defined as a temporary decrease in kidney function that results in the accumulation of creatinine, urea, and other waste products. It has been linked to sodium and water retention and the development of metabolic disturbances such as metabolic acidosis and hyperkalemia.

Continuous Renal Replacement Therapy Market Dynamics

Drivers

• Rise in the number of medical applications   

The increase in the number of medical applications is driving the continuous renal replacement therapy market. Candidates for CRRT include patients with acute renal failure (ARF) who also have significant comorbidities, such as multiple organ failure or defects in their cardiac and circulatory systems, such as cardiac insufficiency and oedema. In addition to renal failure, CRRT can be used to treat multiple organ failure, acute pancreatitis, fulminant hepatitis, and postoperative liver failure.

Furthermore, the clinical advantages of CRRT over intermittent blood purification techniques will be a major factor influencing the growth of the market for continuous renal replacement therapy. Increasing urbanisation and an ageing population are also driving factors in the growth of the continuous renal replacement therapy market.

• Increasing incidences of chronic kidney diseases

One of the major drivers driving the expansion of the continuous expansion renal replacement therapy market is the increased prevalence of chronic kidney disease, which is a key risk factor for diabetes, hypertension, cardiovascular disease, and the inflammatory kidney disease known as glomerulonephritis.

Opportunities

• Rising prevalence of diabetes

The rising prevalence of diabetes and hypertension raises the risk of developing acute kidney injury (AKI), fuelling the market for continuous renal replacement therapy. According to WHO data published in May 2021, 1.13 billion people worldwide are estimated to suffer from hypertension. The rise in high blood pressure rates is likely to have an impact on patients in low and middle-income countries. Every year, hypertension kills approximately 9.4 million people worldwide. It can harm AKI patients and cause acute renal failure. This factor is driving up demand for CRRT systems. Because of increased effectiveness, technological advances in CRRT systems have resulted in a decrease in mortality rate worldwide. An increase in the geriatric population, which is more susceptible to developing AKI, is expected to rise.

Restraints/Challenges

• Growing number of complications linked with CRRT

The growing number of complications associated with CRRT will pose a significant challenge to the market's growth rate. The insertion of a large-bore central venous catheter, which may need to be kept in place for an extended period of time, is required to begin CRRT. Catheter insertion is well-known to cause vascular or visceral injury, bleeding, pneumothorax, hem thorax, and the formation of an arteria-venous fistula. Catheter use for an extended period of time has been linked to venous thrombosis and stenosis.

On the other hand, a scarcity of skilled professionals in developing countries will pose a challenge to the market for continuous renal replacement therapy. Furthermore, an unfavorable reimbursement scenario and a lack of awareness will act as a restraint and further impede the market's growth rate during the forecast period of 2023-2030.

This continuous renal replacement therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the continuous renal replacement therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Continuous Renal Replacement Therapy Market

The high number of COVID-19 patients who develop AKI is expected to drive the market for continuous renal replacement therapy over the forecast period. Prior to COVID-19, CRRT was used to treat about 23,105 AKI patients per year. The need for CRRT appears to be 5 times higher in COVID-19 patients, i.e., 4.9 percent, then in historical populations (0.9 percent). In community cohort datasets, 5%-15% of people hospitalised with COVID-19 required dialysis. Furthermore, in some North American regions, the number of people using CRRT increased by 370 percent over normal levels, increasing demand for the product during the pandemic.

Recent Developments

• In 2021, announced the launch of PrisMax 2 worldwide, the most recent version of the company's next-generation platform. Prisma 2 was created to assist hospitals in meeting the unique demands of the Intensive Care Unit (ICU) while also simplifying the transfer of organ support and continuous renal replacement therapy.

Global Continuous Renal Replacement Therapy Market Scope

The continuous renal replacement therapy market is segmented on the basis of type, usage, end-user and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Dialysates and Replacement Fluids
• Disposables
• Hemofilters
•  Bloodline sets (tubing sets)
•  Other disposables
• Systems

Modality

• Continuous Venovenous Hemofiltration (CVVH)
• Continuous Venovenous Hemodiafiltration (CVVHDF)
• Continuous Venovenous Hemodialysis (CVVHD)
• Slow Continuous Ultrafiltration (SCUF)

Age Group

• Adults
• Pediatrics /Neonates

End-User

• Hospitals
• Ambulatory Centers
• Specially Clinics
• Others

Continuous Renal Replacement Therapy Market Regional Analysis/Insights

The continuous renal replacement therapy market is analysed and market size insights and trends are provided by country, type, usage, end-user and application as referenced above.

The countries covered in the continuous renal replacement therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the continuous renal replacement therapy market because of the rising demand for CRRT procedures in this region. Additionally, advanced innovation in the manufacture of machines and systems will flourish the market's growth rate in this region.

由于亚太地区的技术进步不断提高，预计该地区将在 2023 年至 2030 年的预测期内实现最高增长率。此外，医疗保健支出的增加将推动该地区市场的增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化影响了市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

持续性肾脏替代疗法市场还为您提供详细的市场分析，包括每个国家/地区资本设备医疗支出的增长、持续性肾脏替代疗法市场不同类型产品的安装基数、使用生命线曲线的技术的影响以及医疗监管情景的变化及其对持续性肾脏替代疗法市场的影响。数据涵盖 2011-2021 年的历史时期。

竞争格局和连续肾脏替代治疗市场份额分析

持续性肾脏替代疗法市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对持续性肾脏替代疗法市场的关注有关。

持续性肾脏替代治疗市场的一些主要参与者包括：

• 费森尤斯医疗保健股份公司（德国）
• 百特（美国）
• B. Braun SE（德国）
• 美敦力（爱尔兰）
• NxStage Medical, Inc.（美国）
• 日机装株式会社（日本）
• 旭化成株式会社（日本）
• 东丽医疗株式会社（日本）
• Infomed SA（瑞士）
• Medica SpA（意大利）
• Medical Components, Inc.（美国）
• 宁波天益医疗器械有限公司 (中国)
• 细胞吸附剂（美国）
• BIOMEDICA（奥地利）
• 安觉医疗设备股份有限公司 (中国)
• NIPRO（日本） 

SKU-23577